SCHEMBL171438

SCHEMBL171438

CC(=O)Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
MTNR1A P48039 1/20 0.71
MTNR1B P49286 1/20 0.71
EPHX1 P07099 1/20 0.71
ALDH1A1 P00352 3/20 0.69
MAPT P10636 2/20 0.69
NAPRT Q6XQN6 1/20 0.67
HSD17B10 Q99714 1/20 0.67
PGR P06401 1/20 0.66
KMT2A Q03164 2/20 0.63
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
TAAR1 Q96RJ0 1/20 0.63
POLB P06746 1/20 0.63
MEN1 O00255 1/20 0.63
CRHBP P24387 1/20 0.63
CRHR2 Q13324 1/20 0.63
TGM2 P21980 1/20 0.62
RNF4 P78317 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylether SCHEMBL27428436 0.94 NAPRT (0.76) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL6516221 0.92 KMT2A (0.73) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL18826484 0.86 KMT2A (0.66) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL9162294 0.86 MTNR1B (0.77) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL6304948 0.85 MEN1 (0.59) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL14384396 0.85 MTNR1A (0.76) SMN1; SMN2MTNR1AMTNR1BALDH1A1MAPT
SCHEMBL14192610 0.85 KMT2A (0.63) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1
SCHEMBL5612841 0.85 TDP1 (0.77) HPGDSMN1; SMN2MTNR1AMTNR1BALDH1A1
SCHEMBL2844063 0.85 KMT2A (0.77) HPGDSMN1; SMN2MTNR1AMTNR1BALDH1A1
SCHEMBL8976234 0.84 MTNR1A (0.65) HPGDSMN1; SMN2MTNR1AMTNR1BEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919875-A2 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS Astex Therapeutics Limited (GB) 2008-05-14 EP claimed
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO claimed
WO-2006136829-A2 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2006-12-28 WO claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
CN-110317322-B Particulate amine-functionalized polyaryletherketone polymers and copolymers thereof 塞特工业公司 2022-06-14 CN disclosed
EP-3145975-B1 AMINE-DERIVATISED POLYARYLETHERKETONE COPOLYMERS KETONEX LTD (GB) 2021-03-17 EP disclosed
EP-3145980-B1 PARTICULATE AMINE-FUNCTIONALIZED POLYARYLETHERKETONE POLYMER AND COPOLYMERS THEREOF CYTEC IND INC (US) 2020-04-08 EP disclosed
US-10450408-B2 Method for making polyarylaliphaticetherketone polymers and copolymers thereof KETONEX LIMITED (GB) 2019-10-22 US disclosed
CN-110317322-A Granular amine-functional polyaryl ether ketone polymer and its copolymer 塞特工业公司 2019-10-11 CN disclosed
CN-106661205-B Particulate amine-functionalized polyaryletherketone polymers and copolymers thereof 塞特工业公司 2019-08-06 CN disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
WO-2006136829-A2 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2006-12-28 WO disclosed
US-5034410-A Nitrile and oxo containing amides or thioamides SYNTEX (U.S.A.) INC. (US) 1991-07-23 US disclosed
EP-0023022-B1 COUMARINE COMPOUNDS, PROCESSES FOR THEIR MANUFACTURE AS WELL AS THE INTERMEDIATE PRODUCTS USED PERSE AND THEIR UTILISATION FOR THE DYEING OR PRINTING OF TEXTILES CIBA-GEIGY AG (CH) 1984-04-11 EP disclosed
EP-0023022-A2 Coumarine compounds, processes for their manufacture as well as the intermediate products used perse and their utilisation for the dyeing or printing of textiles CIBA-GEIGY AG (CH) 1981-01-28 EP disclosed
US-4072696-A 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity SYNTEX (U.S.A.) INC. (US) 1978-02-07 US disclosed
US-3965113-A 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity SYNTEX (U.S.A.) INC. (US) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML HPGD 4591/4885SMN1; SMN2 2894/4885MTNR1A 3314/4885
US-20070060754-A1 Alkoxy substituted imidazoquinolines IL2, IFNG, IRF3 HPGD 538/4885SMN1; SMN2 3463/4885MTNR1A 1410/4885
US-10450408-B2 Method for making polyarylaliphaticetherketone polymers and copolymers thereof DAO, DCXR, LOX HPGD 898/4885SMN1; SMN2 4800/4885MTNR1A 3010/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 HPGD 1529/4885SMN1; SMN2 2049/4885MTNR1A 194/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 HPGD 3468/4885SMN1; SMN2 1208/4885MTNR1A 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.